1
|
65
|
M
|
N
|
HCV (active)
|
Y
|
High dose Interleukin-2
|
Gr 1 AST, Gr 1 ALT
|
None
|
PD
|
HCV viral load increased four-fold after IL-2, ipilimumab and temozolomide
|
2
|
56
|
M
|
N
|
HCV (active)
|
Unknown
|
Stereotactic Radiotherapy, then WBRT
|
AST & ALT WNL
|
None
|
PD
|
Possible drug-related hepatitis detected 2 months after receiving 4 doses of ipilimumab
|
3
|
43
|
M
|
N
|
HCV (active)
|
N
|
Temozolomide
|
Gr 2 AST, Gr 2 ALT
|
Normalized by cycle 4
|
Mixed response
|
HCV viral load decreased to undetectable levels after 4 doses of ipilimumab
|
4
|
71
|
M
|
N
|
HCV (active)
|
Y
|
None
|
Gr 1 AST, Gr 1 ALT
|
Gr 2 AST, Gr 3 ALT after cycle 3
|
SD
|
HCV viral load decreased 5-fold to 408,000 IU/mL after 3 doses of ipilimumab; ocular melanoma
|
5
|
56
|
M
|
(multiple tumors involving 25-75% of liver, largest = 6.4 cm)
|
HBV (inactive)
|
Unknown
|
None
|
Gr 1 AST, ALT WNL
|
None
|
PD
|
Concurrent administration of entecovir for prophylaxis against HBV reactivation
|
6
|
60
|
M
|
N
|
HBV (active)
|
Unknown
|
high-dose interleukin-2, talimogene laherparepvec and dacarbazine
|
AST & ALT WNL
|
None
|
PD
|
Tenofovir administration prior to ipi brought HBV viral load from 2950 to 41 IU/mL; became undetectable and remained so throughout ipilimumab
|
7
|
42
|
F
|
(multiple tumors involving 30-40% of liver, largest = 2.7 cm)
|
HBV (inactive)
|
Unknown
|
None
|
AST & ALT WNL
|
None
|
PD
|
HBV viral load undetectable prior to starting ipilimumab
|
8
|
56
|
M
|
N
|
HBV (active)
|
Unknown
|
None
|
AST & ALT WNL
|
None
|
PD
|
Entecavir administration prior to ipi brought HBV viral load from 9560 to 454 IU/mL; became undetectable and remained so throughout ipilimumab
|
9
|
71
|
M
|
N
|
HBV (active)
|
Cirrhosis noted on CT; no confirming path findings
|
None
|
Gr 1 AST, ALT WNL
|
None
|
SD
|
HBV viral load 700 IU/mL prior to starting ipilimumab
|